SpringWorks Therapeutics, Inc.
springworkstx.comNo Longer Reporting
The company has not filed an annual or quarterly report since its Q1 FY2025 10-Q, filed May 9, 2025. Its latest SEC filing is a SCHEDULE 13G/A from Nov 12, 2025.
10-Q for Q1 FY2025, filed May 9, 2025
The sections below describe the company as of the FY2024 annual report.
What Did They Do?
Sells medicines for patients with rare tumors and cancer, including treatments for desmoid tumors and neurofibromatosis, and develops additional targeted cancer treatments.
10-K for FY2024, filed Feb 20, 2025We are a commercial-stage biopharmaceutical company applying a precision medicine approach to developing and commercializing life-changing…View ↗
OGSIVEO® (nirogacestat), our first commercial product, was approved by the United States Food and Drug Administration, or FDA, on November…View ↗
GOMEKLITM (mirdametinib), our second commercial product, was approved by the FDA on February 11, 2025. GOMEKLI is an oral, small molecule…View ↗
How Did They Make Money?
SpringWorks earns product-sale revenue from medicines sold to customers, counted when customers obtain the promised goods. Sales-based royalties are counted when related sales occur or the related promise has been fulfilled, whichever is later.
10-K for FY2024, filed Feb 20, 2025Pursuant to ASC 606, the Company recognizes revenue when its customers obtain control of promised goods or services, in an amount that…View ↗
The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when…View ↗
Product revenue, net: Revenues from product sales are recorded at the net sales price, or “transaction price,” which includes estimates of…View ↗
Royalties: For arrangements that include sales-based royalties, including commercial milestone payments based on the level of sales, and…View ↗
$191.6M
-
10-K for FY2024, filed Feb 20, 2025
$191.6M ↗
Who Were Their Customers?
SpringWorks sells OGSIVEO and GOMEKLI in the U.S. principally through third-party specialty drug distributors and specialty pharmacies.
10-K for FY2024, filed Feb 20, 2025CustomersView ↗
Did Revenues Turn Into Profits?
No. It lost $258.1M in FY2024.
10-K for FY2024, filed Feb 20, 2025
−$278.1MView ↗
10-K for FY2024, filed Feb 20, 2025
−$258.1MView ↗
10-K for FY2024, filed Feb 20, 2025
−$180.1MView ↗
How Were They Changing?
- Net income
-
Sources
10-Q for Q1 FY2025, filed May 10, 2025
−$83.2MView ↗
- ▼ −5% (Loss)
- vs −$87.4M in Q1 FY2024
-
Jul 1, 2025
Merck completed its acquisition of SpringWorks
SpringWorks shares were converted into a right to receive $47.00 in cash.
Sources
8-K, filed Jul 1, 2025
Pursuant to the Merger Agreement, at the effective time of the Merger (the “Effective Time”), each share of common stock, par value $0.0001…View ↗
Grew. Revenue grew 5.5x in 4 years, from $35M in FY2020 to $191.6M in FY2024, about 53% a year.
From clinical development to commercial sales
The older report described SpringWorks as clinical-stage, with nirogacestat and mirdametinib as product candidates. The latest report describes a commercial-stage company selling approved medicines while continuing development in additional indications and other oncology candidates.
10-K for FY2021, filed Feb 24, 2022 10-K for FY2024, filed Feb 20, 2025We are a clinical-stage biopharmaceutical company applying a precision medicine approach to acquiring, developing and commercializing…View ↗
We are a commercial-stage biopharmaceutical company applying a precision medicine approach to developing and commercializing life-changing…View ↗
OGSIVEO® (nirogacestat), our first commercial product, was approved by the United States Food and Drug Administration, or FDA, on November…View ↗
GOMEKLITM (mirdametinib), our second commercial product, was approved by the FDA on February 11, 2025. GOMEKLI is an oral, small molecule…View ↗
Who Did They Compete With?
Competes with Bayer, Eisai, Immunome, Iterion Therapeutics, MedPacto, Parabilis Medicines, AstraZeneca, Array BioPharma, Chia Tai Tianqing Pharmaceutical Group, Healx, Infixion Bioscience, NFlection Therapeutics, Novartis International, Pasithea Therapeutics, Shanghai Fosun Pharmaceutical (Group), Shanghai Kechow Pharma, Amgen, Black Diamond Therapeutics, Boehringer Ingelheim International, and Chugai Pharmaceutical
10-K for FY2024, filed Feb 20, 2025OGSIVEO is the first and currently only FDA-approved therapy for desmoid tumors, with approval received on November 27, 2023. We are aware…View ↗
Loading...
